Is it safe to administer DayQuil, which contains dextromethorphan, to a patient who is taking Auvelity (bupropion + dextromethorphan) once daily?

Risk of Serotonin Syndrome with DayQuil and Auvelity

At 10 mg dextromethorphan per 30 mL of DayQuil taken once daily alongside once-daily Auvelity, the risk of serotonin syndrome is low but requires monitoring, particularly in the first 24-48 hours after adding DayQuil. The total daily dextromethorphan exposure would be approximately 55 mg (45 mg from Auvelity + ~10 mg from DayQuil), which remains below typical abuse doses but represents additive serotonergic activity.

Understanding the Drug Interaction

Auvelity contains 45 mg dextromethorphan combined with 105 mg bupropion specifically designed to inhibit CYP2D6 metabolism of dextromethorphan, maintaining therapeutic levels 1. When you add external dextromethorphan from DayQuil, you're introducing additional serotonergic substrate into a system where metabolism is already intentionally slowed.

The 2020 AACAP guidelines explicitly warn that caution should be exercised when combining two or more non-MAOI serotonergic drugs, including cough/cold/allergy medications containing dextromethorphan 2. The guideline emphasizes starting any second serotonergic drug at a low dose, increasing slowly, and monitoring for symptoms especially in the first 24-48 hours after dosage changes.

Clinical Decision Framework

Low-Risk Scenario (Your Patient)

• Once-daily Auvelity (not twice daily)
• Low-dose DXM exposure from DayQuil (~10 mg)
• Short-term use for acute cold symptoms

Recommendation: This can be done cautiously with close monitoring. The patient should:

• Take DayQuil at least 8 hours separated from Auvelity dose
• Use for shortest duration necessary (typically 3-7 days for cold symptoms)
• Watch for early serotonin syndrome symptoms: confusion, agitation, tremors, tachycardia, diaphoresis, diarrhea
• Contact provider immediately if any concerning symptoms develop

Higher-Risk Scenarios to Avoid

• Twice-daily Auvelity (90 mg DXM/day) + DayQuil = excessive exposure
• Multiple DXM-containing products simultaneously
• Prolonged concurrent use beyond acute illness period
• Patients who are CYP2D6 poor metabolizers 1

Serotonin Syndrome Recognition

The 2020 AACAP guidelines detail the clinical presentation 2:

• Mental status changes: confusion, agitation, anxiety
• Neuromuscular hyperactivity: tremors, clonus, hyperreflexia, muscle rigidity
• Autonomic hyperactivity: hypertension, tachycardia, tachypnea, diaphoresis, shivering
• Advanced symptoms: fever, seizures, arrhythmias, unconsciousness (potentially fatal)

Symptoms typically arise within 24-48 hours after combining medications. Treatment requires immediate discontinuation of all serotonergic agents and hospital-based supportive care with continuous cardiac monitoring.

Practical Alternatives

For cough suppression without DXM:

• Menthol inhalation (short-acting but effective) 3
• Honey and lemon home remedy 3
• Ipratropium bromide for URI-related cough 4, 5
• Simple voluntary cough suppression techniques 3

The 2006 ACCP guidelines note that dextromethorphan at 60 mg shows maximum cough reflex suppression 3, but for acute viral URI, evidence for DXM efficacy is actually limited 4, 5.

Key Monitoring Points

If proceeding with concurrent use:

1. Temporal separation: Minimum 8 hours between doses
2. Duration limit: Use DayQuil only for acute symptom period (typically ≤7 days)
3. Symptom surveillance: Daily check-in for first 48 hours, then as needed
4. Patient education: Clear instructions on warning signs requiring immediate medical attention
5. Avoid dose escalation: Do not exceed recommended DayQuil dosing

Important Caveat

If the patient were on twice-daily Auvelity (90 mg DXM/day), adding DayQuil would NOT be recommended due to excessive cumulative dextromethorphan exposure. The Auvelity prescribing information specifically instructs screening patients to determine if they are receiving any other medications containing dextromethorphan 1, reflecting the manufacturer's awareness of this interaction risk.

The once-daily dosing in your scenario provides a margin of safety, but vigilance remains essential given the documented risk of serotonin syndrome when combining serotonergic agents, even those not classified as MAOIs 2.